Skip to main
ATRC

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure is a leader in innovative surgical treatments for conditions such as atrial fibrillation and post-operative pain management, with a strong portfolio of products and a focus on sales and distribution in the United States. A potential increase in adoption through new quality metrics and growth in new verticals could lead to strong revenue growth and potential upside for the company. With a solid financial outlook and a strong position in the market, AtriCure is poised for continued success in the future.

Bears say

AtriCure is expected to experience stronger-than-expected revenue growth due to a faster 10 point penetration rate in their cardiac ablation and left atrial appendage management product lines, potentially resulting in an additional $27 million in revenue in 2027 and $55 million in 2028. Furthermore, the company anticipates further growth in international sales from the upcoming launch of their Flex-Mini and Pro-Mini products in Europe. However, softness in the UK and Germany, as well as pressure from competing procedures in the US, may hinder overall revenue growth.

AtriCure (ATRC) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Strong Buy based on their latest research and market trends.

According to 7 analysts, AtriCure (ATRC) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.